Technology ID

Chimeric Antigen Receptor (CAR) that Targets Chemokine Receptor CCR4 and its Use in Treating Cancer

Lead Inventor
Perera, Liyanage (NCI)
Waldmann, Thomas (NCI)
Therapeutic Areas
Development Stages
Lead IC

The chemokine receptor, CCR4 is a seven transmembrane G protein-coupled cell surface receptor molecule with selective expression on cells of the hematopoietic system. In adult T cell leukemia (ATL), the cell-surface expression of CCR4 on leukemic cells has been found to be nearly universal. Therefore, a CCR4-directed chimeric antigen receptor (CAR) -cell may provide an effective therapeutic against ATL.

Researchers at the National Cancer Institute (NCI), Lymphoid Malignancies Branch, developed a lentivirus-derived CAR against the CCR4 molecule. The CAR can be directed to either genetically modified autologous or to allogeneic T or natural killer (NK) -cells to develop the ATL therapy. This technology includes a method of identifying lymphoid or solid tumors that produce CCR4 mRNA and then utilizing CD3+ T cells and/or NK cells to generate genetically modified T cells and/or NK cells (autologous or allogeneic) that express the CCR4 directed CAR. The identified malignancy can then be treated with the infusion of genetically modified T/NK cells. 

The NCI seeks licensing and/or co-development of an adoptive cellular therapeutic modality that targets CCR4, which is overexpressed in certain lymphoid malignancies as well as solid tumors.

Competitive Advantages:

  • CCR4 is a more recent target for cell-based immunotherapy
  • Allogenic NK cells would enable wider use of cell-based therapies

Commercial Applications:

  • Identification and treatment of CCR4 mRNA producing lymphoid or solid neoplasms
  • CCR4 putative biomarker in lung adenocarcinoma and other cancers
Licensing Contact:
Bhattacharya, Ramona